Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Susonity
Chuo-ku, Tokyo, Japannxera.life ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Susonity is a Japanese biotechnology joint venture established in 2022 by Nxera Pharma (formerly Sosei Heptares) and Kowa Company. The entity was created specifically to develop and commercialize a portfolio of novel G protein-coupled receptor (GPCR) agonists within the Japanese market. Its primary asset is HTL0048141, a first-in-class selective GPR52 agonist currently in clinical development for the treatment of schizophrenia. By combining Nxera's structure-based drug design expertise with Kowa's commercial strength in Japan, Susonity aims to address significant unmet needs in psychiatric and neurological disorders.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Nxera PharmaKowa Company
Beyond the preview
Go deeper on Susonity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Susonity.